drugset / Trial / NCT04025593
Biomarker Guided Treatment in DLBCL
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma
Timeline
- Start
- 2019-07-17
- Primary completion
- 2021-07-01
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 10 mg/m2 | — |
| Subject | Ibrutinib | Small molecule | 420 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | Tucidinostat | Small molecule | 20 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 60 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | — |